Cristina Scerbatiuc

Cristina Scerbatiuc

Auto-generated profile, based on publicly available information

Cristina Scerbatiuc


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2023 in Public Health, Economy and Management in Medicine
Verified
Journal Article
Open access
CSCristina Scerbatiuc
Cristina Scerbatiuc
EBEugeniu Bendelic
Eugeniu Bendelic
IMIon Moldovanu
Ion Moldovanu
IJIon Jeru
Ion Jeru
Migraine is often associated with photophobia, phonophobia, dizziness, sometimes vomiting, and fatigue. Usually, in the treatment of migraine attacks, non-steroidal anti-inflammatory drugs, ergot preparations, triptans are recommended. Determination of ophthalmic features in patients with migraine and study of the efficacy of Timolol 0.5% in migraine attack. The literature review presents the data of some authors who used ophthalmic drops sol.Timolol 0.5% in migraine patients. Cases of complete resolution of ophthalmoplegia and visual field deficiency have been reported in patients with hemiplegic migraine. This method of treatment may have a beneficial effect in preventing migraine attacks. Timolol eye drops 0.5% is an effective, well-tolerated, safe and simple remedy in crisis and preventive anti-migraine treatment.

18 November 2024 in Public Health, Economy and Management in Medicine
Verified
Journal Article
Open access
CSCristina Scerbatiuc
Cristina Scerbatiuc
The prevalence of diabetic retinopathy (DR) continues to increase in pregnant women. The lack of studies on the safety and efficacy of current treatment options during pregnancy makes management of the disease particularly challenging. All pregnant women with diabetes should undergo prenatal screening for DR as well as receive advice on the course and management of DR during pregnancy. Optimal control of blood glucose and blood pressure should be recommended. For patients with proliferative diabetic retinopathy (PDR) in the absence of significant diabetic macular edema (DME), pan-retinal photocoagulation remains a safe and effective treatment option. Significant diabetic macular edema can be treated with a focal laser if focal leakage areas are identified in the macula, intravitreally introduced steroids or anti-VEGF agents. The theoretical risk of anti-VEGF agents to the fetus must be considered so patients should be informed of the risks and benefits of anti-VEGF therapy before treatment is initiated. When deciding to treat with anti-VEGF agents, Ranibizumab should be the agent of choice. In conclusion, ophthalmologists should make treatment decisions in pregnant patients with DR on a case-by-case basis, taking into account disease severity, risk of permanent vision loss, gestational term, and patient preferences.

1 October 2024 in Moldovan Journal of Health Sciences
Verified
Journal Article
Closed access
CSCristina Scerbatiuc
Cristina Scerbatiuc
Introduction The onset and development of diabetic retinopathy are more common during pregnancy. Pregnancy has no long-term effect on diabetic retinopathy; however, in 50-70% of cases, changes in retinopathy continues. The probability of worsening is highest in the second trimester and up to one year postpartum. Additional factors that have been associated with disease progression include duration of diabetes, the degree of retinopathy at the time of conception, management of hyperglycemia, anemia, and development of associated hypertension. In cases of severe non-proliferative retinopathy, it is recommended to promptly initiate laser photocoagulation rather than wait for early proliferative changes. Maintaining good diabetic control before and during pregnancy can help prevent disease progression and serious vision loss. Material and methods Diabetic retinopathy management in pregnancy was the subject of a comprehensive review of the scientific and medical literature. A structured search was performed in the PubMed, Scopus and HINARI databases, considering relevant articles published in the last 10 years. The search terms used (in English) were: „Diabetic retinopathy”; „pregnancy”; „laser photocoagulation”; „intravitreal steroids”; „anti-vascular endothelial growth factor”. Results It is suggested that women with diabetes receive pre-conception and post-pregnancy counselling from a multidisciplinary team including an ophthalmologist, endocrinologist, and perinatologist, as diabetic retinopathy may worsen during pregnancy. The risk of progression of the disease and the importance of appropriate metabolic control before and during pregnancy should be clearly explained to the patient. Careful monitoring is required in patients with advanced gestation, significant retinopathy, concomitant hypertension, and nephropathy. Conclusion The risk of retinopathy development may increase during pregnancy. Serious effects can arise for both the mother and the fetus, even though retinopathy is not common during pregnancy. It is possible to avoid significant retinopathy by carefully planning a young diabetic woman's pregnancy and proceeding promptly to laser photocoagulate in cases of severe non-proliferative retinopathy. A tendency for regress is frequently seen in diabetic retinopathy during the post-natal period. Subsequent pregnancies do not significantly increase the risk of progression if the retinopathy is stable before pregnancy.